ClinicalTrials.gg
CompletedNCT06242691Updated Jun 5, 2026Results posted

Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002)

A Phase 1/2 interventional study of MK-1200 and Antiemetic in Advanced Solid Tumors, sponsored by Merck Sharp & Dohme LLC. Completed at 16 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the efficacy and safety of MK-1200 monotherapy in participants with advanced/metastatic gastric/gastroesophageal junction (GEJ) cancer, esophageal cancer, biliary tract cancer, and pancreatic ductal adenocarcinoma who have received, or been intolerant to, all treatments known to confer clinical benefit. Part 1 of the study will be a dose escalation to determine the maximum tolerated dose (MTD). Part 2 will evaluate safety and efficacy of MK-1200 at 2 different doses

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed advanced (unresectable and/or ) solid tumor: gastric cancer (including gastroesophageal junction cancer), esophageal cancer, biliary tract cancer, or pancreatic ductal adenocarcinoma
  • Participants who experienced Adverse Events (AEs) due to previous anticancer therapies must have recovered to \< Grade 1 or baseline
  • (HIV)-infected participants must have well controlled HIV on antiretroviral therapy
  • surface antigen (HBsAg) positive participants are eligible if they have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load
  • Participants with a history of Virus (HCV) infection are eligible if HCV viral load is undetectable
  • Received and progressed on or after 1 or 2

Exclusion criteria

Exclusion Criteria:

  • Active severe digestive disease
  • History of acute myocardial infarction; unstable angina; stroke or within 6 months prior to the first dose of study intervention
  • Diabetes or hypertension that cannot be controlled by medication
  • -infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Received prior systemic anticancer therapy including agents within 4 weeks before study intervention
  • Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring
  • Known additional that is progressing or has required active treatment within the past 2 years
  • Known active central nervous system (CNS) and/or carcinomatous meningitis
  • Active infection requiring systemic therapy
  • Have not adequately recovered from major surgery or have ongoing surgical complications
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Part 1: MK-1200

    In Part 1, participants will receive escalating doses of MK-1200 via intravenous (IV) infusion every 2 weeks (Q2W) until any discontinuation criteria are met.

    Biological: MK-1200 · Drug: Antiemetic

  • Experimental
    Part 2: MK-1200 Cohort A

    In Part 2, participants in Cohort A will receive either Dose 1 or Dose 2 of MK-1200 (determined from Part 1) via IV infusion Q2W until any discontinuation criteria are met.

    Biological: MK-1200 · Drug: Antiemetic

  • Experimental
    Part 2: MK-1200 Cohort B

    In Part 2, participants in Cohort B will receive Dose 1 of MK-1200 (determined from Part 1) via IV infusion Q2W until any discontinuation criteria are met.

    Biological: MK-1200 · Drug: Antiemetic

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Part 1

    The occurrence of any of the following toxicities within 28 days after the first dose of study intervention were considered a DLT, if assessed by the investigator to be possibly, probably, or definitely related to study intervention administration: * Grade 4 nonhematologic toxicity (not laboratory). Any nonhematologic AE ≥Grade 3 in severity was considered a DLT, with pre-specified exceptions * Any Grade 3 or Grade 4 laboratory value (hematologic or nonhematologic), with pre-specified exceptions * Febrile neutropenia Grade 3 or Grade 4 as prespecified by the protocol * Prolonged delay (\>2 weeks) in initiating Cycle 2 due to intervention-related toxicity * Any intervention-related toxicity that caused the participant to discontinue intervention during Cycle 1 * Missed \>25% of MK-1200 doses as a result of drug-related AEs during the first cycle * Grade 5 toxicity

    Time frame: During the first two 14-day cycles (Up to approximately 28 days)

  2. Number of Participants Who Experience One or More Adverse Events (AEs) - Part 1 & Part 2

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced an AE is reported for each arm.

    Time frame: Up to approximately 12 months

  3. Number of Participants Who Discontinue Study Intervention Due to an AE - Part 1 & Part 2

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued study intervention due to an AE is reported for each arm.

    Time frame: Up to approximately 9 months

Secondary outcomes

  1. Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) - Part 2 Cohort A

    ORR was defined as the percentage of participants who have achieved confirmed Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by blinded independent central review (BICR). As pre-specified by the protocol, this analysis was to only include all participants randomized to Part 2 Cohort A who received at least 1 dose of study intervention.

    Time frame: Up to approximately 13 months

  2. ORR Per RECIST 1.1 as Assessed by Investigator - Part 1 & Part 2 Cohort B

    ORR was defined as the percentage of participants who have achieved confirmed Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by the investigator.

    Time frame: Up to approximately 13 months

  3. Area Under the Concentration Versus Time Curve From Time 0 to 336 Hours (AUC0-336) of MK-1200-Antibody-Drug Conjugate (ADC) - Parts 1 and 2

    AUC0-336 was defined as the area under the concentration versus time curve of MK-1200-ADC from time 0 to 336 Hours. Blood samples were collected at pre-specified timepoints to determine the AUC0-336 of the MK-1200-ADC.

    Time frame: Cycle 1 Day 1: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.

  4. AUC0-336 of the Conjugated Toxin Payload (KL610023) - Parts 1 and 2

    AUC0-336 was defined as the area under the concentration versus time curve of KL610023 from time 0 to 336 Hours. Blood samples were collected at pre-specified timepoints to determine AUC0-336 of KL610023.

    Time frame: Cycle 1 Day 1: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.

  5. Area Under the Concentration Versus Time Curve From Time 0 to the End of the Dosing Period (AUC0-tau) of MK-1200-ADC - Parts 1 and 2

    AUC0-tau was defined as the area under the concentration versus time curve of MK-1200-ADC from time 0 to the end of the 14-day dosing period (Cycle 4, 336 hours post-dose). Blood samples were collected at pre-specified timepoints to determine AUC0-tau of the MK-1200-ADC.

    Time frame: Cycle 4 Day 1: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.

  6. AUC0-tau of KL610023 - Parts 1 and 2

    AUC0-tau is defined as the area under the concentration versus time curve of KL610023 from time 0 to the end of the 14-day dosing period (Cycle 4, 336 hours post-dose). Blood samples were collected at pre-specified timepoints to determine AUC0-tau of KL610023.

    Time frame: Cycle 4 Day 1: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.

  7. Minimum Concentration (Cmin) of MK-1200-ADC - Part 1 & Part 2

    Cmin was defined as the minimum concentration of MK-1200-ADC observed in plasma after its administration and just prior to administration of a subsequent dose. Blood samples were collected at pre-specified timepoints to determine Cmin of the MK-1200-ADC.

    Time frame: Day 1 of Cycles 1 and 4: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.

  8. Cmin of KL610023 - Part 1 & Part 2

    Cmin was defined as the minimum concentration of KL610023 observed in plasma after its administration and just prior to administration of a subsequent dose. Blood samples were collected at pre-specified timepoints to determine Cmin of KL610023.

    Time frame: Day 1 of Cycles 1 and 4: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.

  9. Maximum Concentration (Cmax) of MK-1200-ADC - Part 1 & Part 2

    Cmax was defined as the maximum or 'peak' concentration of MK-1200-ADC observed after its administration. Blood samples were collected at pre-specified timepoints to determine Cmax of the MK-1200-ADC.

    Time frame: Day 1 of Cycles 1 and 4: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.

  10. Cmax of KL610023 - Part 1 & Part 2

    Cmax was defined as the maximum or 'peak' concentration of KL610023 observed after its administration. Blood samples were collected at pre-specified timepoints to determine Cmax of KL610023.

    Time frame: Day 1 of Cycles 1 and 4: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.

  11. Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR - Part 2 Cohort A

    For participants demonstrating a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from the first documented evidence of a CR or a PR until Progressive Disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. As pre-specified by the protocol, DOR for Part 2 Cohort A was planned to be assessed by BICR and was to include all participants randomized to Part 2 Cohort A who received at least one dose of study intervention.

    Time frame: Up to approximately 13 months

  12. DOR Per RECIST 1.1 as Assessed by Investigator - Part 1 & Part 2 Cohort B

    For participants demonstrating a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from the first documented evidence of a CR or a PR until PD or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by the investigator is reported.

    Time frame: Up to approximately 13 months

  13. Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by BICR - Part 2 Cohort A

    PFS was defined as the time from randomization to the first documented PD by BICR or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. As pre-specified by the protocol, PFS for Part 2 Cohort A was planned to be assessed by BICR and was to only include all participants randomized to Part 2 Cohort A who received at least one dose of study intervention.

    Time frame: Up to approximately 13 months

  14. PFS Per RECIST 1.1 as Assessed by Investigator - Part 1 & Part 2 Cohort B

    PFS was defined as the time from randomization to the first documented PD by investigator or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS as assessed by the investigator is reported.

    Time frame: Up to approximately 13 months

  15. Overall Survival (OS) - Part 1 & Part 2

    OS was defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 13 months

07

Results

Posted Jun 5, 2026

Participant flow

Participant flow — Overall Study
MilestonePart 1: MK-1200 3.6 mg/kgPart 1: MK-1200 4.2 mg/kgPart 1: MK-1200 4.8 mg/kgPart 2: MK-1200 Cohort A (Part 2-Not Enrolled)Part 2: MK-1200 Cohort B (Part 2-Not Enrolled)
Started35500
Completed00000
Not completed35500
Withdrew: Death25400
Withdrew: Sponsor decision10000
Withdrew: Withdrawal by subject00100

Outcome measures

PrimaryNumber of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Part 1

The occurrence of any of the following toxicities within 28 days after the first dose of study intervention were considered a DLT, if assessed by the investigator to be possibly, probably, or definitely related to study intervention administration: * Grade 4 nonhematologic toxicity (not laboratory). Any nonhematologic AE ≥Grade 3 in severity was considered a DLT, with pre-specified exceptions * Any Grade 3 or Grade 4 laboratory value (hematologic or nonhematologic), with pre-specified exceptions * Febrile neutropenia Grade 3 or Grade 4 as prespecified by the protocol * Prolonged delay (\>2 weeks) in initiating Cycle 2 due to intervention-related toxicity * Any intervention-related toxicity that caused the participant to discontinue intervention during Cycle 1 * Missed \>25% of MK-1200 doses as a result of drug-related AEs during the first cycle * Grade 5 toxicity

Time frame:
During the first two 14-day cycles (Up to approximately 28 days)
Reported as:
Count of participants · Participants
Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Part 1
ParticipantsPart 1: MK-1200 3.6 mg/kgPart 1: MK-1200 4.2 mg/kgPart 1: MK-1200 4.8 mg/kgPart 2: MK-1200 Cohort A (Part 2-Not Enrolled)Part 2: MK-1200 Cohort B (Part 2-Not Enrolled)
Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Part 1001——
PrimaryNumber of Participants Who Experience One or More Adverse Events (AEs) - Part 1 & Part 2

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced an AE is reported for each arm.

Time frame:
Up to approximately 12 months
Reported as:
Count of participants · Participants
Number of Participants Who Experience One or More Adverse Events (AEs) - Part 1 & Part 2
ParticipantsPart 1: MK-1200 3.6 mg/kgPart 1: MK-1200 4.2 mg/kgPart 1: MK-1200 4.8 mg/kgPart 2: MK-1200 Cohort A (Part 2-Not Enrolled)Part 2: MK-1200 Cohort B (Part 2-Not Enrolled)
Number of Participants Who Experience One or More Adverse Events (AEs) - Part 1 & Part 2355——
PrimaryNumber of Participants Who Discontinue Study Intervention Due to an AE - Part 1 & Part 2

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued study intervention due to an AE is reported for each arm.

Time frame:
Up to approximately 9 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinue Study Intervention Due to an AE - Part 1 & Part 2
ParticipantsPart 1: MK-1200 3.6 mg/kgPart 1: MK-1200 4.2 mg/kgPart 1: MK-1200 4.8 mg/kgPart 2: MK-1200 Cohort A (Part 2-Not Enrolled)Part 2: MK-1200 Cohort B (Part 2-Not Enrolled)
Number of Participants Who Discontinue Study Intervention Due to an AE - Part 1 & Part 2000——
SecondaryObjective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) - Part 2 Cohort A

ORR was defined as the percentage of participants who have achieved confirmed Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by blinded independent central review (BICR). As pre-specified by the protocol, this analysis was to only include all participants randomized to Part 2 Cohort A who received at least 1 dose of study intervention.

Time frame:
Up to approximately 13 months

No measurements were reported for this outcome.

SecondaryORR Per RECIST 1.1 as Assessed by Investigator - Part 1 & Part 2 Cohort B

ORR was defined as the percentage of participants who have achieved confirmed Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by the investigator.

Time frame:
Up to approximately 13 months
Reported as:
Number · Percentage of Participants
ORR Per RECIST 1.1 as Assessed by Investigator - Part 1 & Part 2 Cohort B
Percentage of ParticipantsPart 1: MK-1200 3.6 mg/kgPart 1: MK-1200 4.2 mg/kgPart 1: MK-1200 4.8 mg/kgPart 2: MK-1200 Cohort A (Part 2-Not Enrolled)Part 2: MK-1200 Cohort B (Part 2-Not Enrolled)
ORR Per RECIST 1.1 as Assessed by Investigator - Part 1 & Part 2 Cohort B0 (0.0 to 70.8)0 (0.0 to 52.2)0 (0.0 to 52.2)——
SecondaryArea Under the Concentration Versus Time Curve From Time 0 to 336 Hours (AUC0-336) of MK-1200-Antibody-Drug Conjugate (ADC) - Parts 1 and 2

AUC0-336 was defined as the area under the concentration versus time curve of MK-1200-ADC from time 0 to 336 Hours. Blood samples were collected at pre-specified timepoints to determine the AUC0-336 of the MK-1200-ADC.

Time frame:
Cycle 1 Day 1: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
Reported as:
Geometric mean · hr*μg/mL
Area Under the Concentration Versus Time Curve From Time 0 to 336 Hours (AUC0-336) of MK-1200-Antibody-Drug Conjugate (ADC) - Parts 1 and 2
hr*μg/mLPart 1: MK-1200 3.6 mg/kgPart 1: MK-1200 4.2 mg/kgPart 1: MK-1200 4.8 mg/kgPart 2: MK-1200 Cohort A (Part 2-Not Enrolled)Part 2: MK-1200 Cohort B (Part 2-Not Enrolled)
Area Under the Concentration Versus Time Curve From Time 0 to 336 Hours (AUC0-336) of MK-1200-Antibody-Drug Conjugate (ADC) - Parts 1 and 22840 ± 49.74310 ± 40.93770 ± 24.5——
SecondaryAUC0-336 of the Conjugated Toxin Payload (KL610023) - Parts 1 and 2

AUC0-336 was defined as the area under the concentration versus time curve of KL610023 from time 0 to 336 Hours. Blood samples were collected at pre-specified timepoints to determine AUC0-336 of KL610023.

Time frame:
Cycle 1 Day 1: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
Reported as:
Geometric mean · hr*ng/mL
AUC0-336 of the Conjugated Toxin Payload (KL610023) - Parts 1 and 2
hr*ng/mLPart 1: MK-1200 3.6 mg/kgPart 1: MK-1200 4.2 mg/kgPart 1: MK-1200 4.8 mg/kgPart 2: MK-1200 Cohort A (Part 2-Not Enrolled)Part 2: MK-1200 Cohort B (Part 2-Not Enrolled)
AUC0-336 of the Conjugated Toxin Payload (KL610023) - Parts 1 and 2329 ± 40.8748 ± 18.9583 ± 173.9——
SecondaryArea Under the Concentration Versus Time Curve From Time 0 to the End of the Dosing Period (AUC0-tau) of MK-1200-ADC - Parts 1 and 2

AUC0-tau was defined as the area under the concentration versus time curve of MK-1200-ADC from time 0 to the end of the 14-day dosing period (Cycle 4, 336 hours post-dose). Blood samples were collected at pre-specified timepoints to determine AUC0-tau of the MK-1200-ADC.

Time frame:
Cycle 4 Day 1: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
Reported as:
Geometric mean · hr*μg/mL
Area Under the Concentration Versus Time Curve From Time 0 to the End of the Dosing Period (AUC0-tau) of MK-1200-ADC - Parts 1 and 2
hr*μg/mLPart 1: MK-1200 3.6 mg/kgPart 1: MK-1200 4.2 mg/kgPart 1: MK-1200 4.8 mg/kgPart 2: MK-1200 Cohort A (Part 2-Not Enrolled)Part 2: MK-1200 Cohort B (Part 2-Not Enrolled)
Area Under the Concentration Versus Time Curve From Time 0 to the End of the Dosing Period (AUC0-tau) of MK-1200-ADC - Parts 1 and 23130 ± 40.34070 ± 35.82580 ± NA——
SecondaryAUC0-tau of KL610023 - Parts 1 and 2

AUC0-tau is defined as the area under the concentration versus time curve of KL610023 from time 0 to the end of the 14-day dosing period (Cycle 4, 336 hours post-dose). Blood samples were collected at pre-specified timepoints to determine AUC0-tau of KL610023.

Time frame:
Cycle 4 Day 1: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
Reported as:
Geometric mean · hr*ng/mL
AUC0-tau of KL610023 - Parts 1 and 2
hr*ng/mLPart 1: MK-1200 3.6 mg/kgPart 1: MK-1200 4.2 mg/kgPart 1: MK-1200 4.8 mg/kgPart 2: MK-1200 Cohort A (Part 2-Not Enrolled)Part 2: MK-1200 Cohort B (Part 2-Not Enrolled)
AUC0-tau of KL610023 - Parts 1 and 2319 ± 25.9723 ± 19.9308 ± NA——
SecondaryMinimum Concentration (Cmin) of MK-1200-ADC - Part 1 & Part 2

Cmin was defined as the minimum concentration of MK-1200-ADC observed in plasma after its administration and just prior to administration of a subsequent dose. Blood samples were collected at pre-specified timepoints to determine Cmin of the MK-1200-ADC.

Time frame:
Day 1 of Cycles 1 and 4: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
Reported as:
Geometric mean · μg/mL
Minimum Concentration (Cmin) of MK-1200-ADC - Part 1 & Part 2
μg/mLPart 1: MK-1200 3.6 mg/kgPart 1: MK-1200 4.2 mg/kgPart 1: MK-1200 4.8 mg/kgPart 2: MK-1200 Cohort A (Part 2-Not Enrolled)Part 2: MK-1200 Cohort B (Part 2-Not Enrolled)
Cycle 1 Day 10.176 ± 67.4NA ± NANA ± NA——
Cycle 4 Day 1NA ± NA0.167 ± 64.70.390 ± NA——
SecondaryCmin of KL610023 - Part 1 & Part 2

Cmin was defined as the minimum concentration of KL610023 observed in plasma after its administration and just prior to administration of a subsequent dose. Blood samples were collected at pre-specified timepoints to determine Cmin of KL610023.

Time frame:
Day 1 of Cycles 1 and 4: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
Reported as:
Geometric mean · ng/mL
Cmin of KL610023 - Part 1 & Part 2
ng/mLPart 1: MK-1200 3.6 mg/kgPart 1: MK-1200 4.2 mg/kgPart 1: MK-1200 4.8 mg/kgPart 2: MK-1200 Cohort A (Part 2-Not Enrolled)Part 2: MK-1200 Cohort B (Part 2-Not Enrolled)
Cycle 1 Day 1NA ± NANA ± NANA ± NA——
Cycle 4 Day 1NA ± NANA ± NANA ± NA——
SecondaryMaximum Concentration (Cmax) of MK-1200-ADC - Part 1 & Part 2

Cmax was defined as the maximum or 'peak' concentration of MK-1200-ADC observed after its administration. Blood samples were collected at pre-specified timepoints to determine Cmax of the MK-1200-ADC.

Time frame:
Day 1 of Cycles 1 and 4: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
Reported as:
Geometric mean · μg/mL
Maximum Concentration (Cmax) of MK-1200-ADC - Part 1 & Part 2
μg/mLPart 1: MK-1200 3.6 mg/kgPart 1: MK-1200 4.2 mg/kgPart 1: MK-1200 4.8 mg/kgPart 2: MK-1200 Cohort A (Part 2-Not Enrolled)Part 2: MK-1200 Cohort B (Part 2-Not Enrolled)
Cycle 1 Day 160.5 ± 34.289.0 ± 42.973.7 ± 13.3——
Cycle 4 Day 168.1 ± 18.284.7 ± 36.370.7 ± NA——
SecondaryCmax of KL610023 - Part 1 & Part 2

Cmax was defined as the maximum or 'peak' concentration of KL610023 observed after its administration. Blood samples were collected at pre-specified timepoints to determine Cmax of KL610023.

Time frame:
Day 1 of Cycles 1 and 4: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
Reported as:
Geometric mean · ng/mL
Cmax of KL610023 - Part 1 & Part 2
ng/mLPart 1: MK-1200 3.6 mg/kgPart 1: MK-1200 4.2 mg/kgPart 1: MK-1200 4.8 mg/kgPart 2: MK-1200 Cohort A (Part 2-Not Enrolled)Part 2: MK-1200 Cohort B (Part 2-Not Enrolled)
Cycle 1 Day 16.26 ± 49.412.0 ± 21.615.8 ± 85.2——
Cycle 4 Day 16.50 ± 31.115.5 ± 55.33.64 ± NA——
SecondaryDuration of Response (DOR) Per RECIST 1.1 as Assessed by BICR - Part 2 Cohort A

For participants demonstrating a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from the first documented evidence of a CR or a PR until Progressive Disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. As pre-specified by the protocol, DOR for Part 2 Cohort A was planned to be assessed by BICR and was to include all participants randomized to Part 2 Cohort A who received at least one dose of study intervention.

Time frame:
Up to approximately 13 months

No measurements were reported for this outcome.

SecondaryDOR Per RECIST 1.1 as Assessed by Investigator - Part 1 & Part 2 Cohort B

For participants demonstrating a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from the first documented evidence of a CR or a PR until PD or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by the investigator is reported.

Time frame:
Up to approximately 13 months

No measurements were reported for this outcome.

SecondaryProgression-Free Survival (PFS) Per RECIST 1.1 as Assessed by BICR - Part 2 Cohort A

PFS was defined as the time from randomization to the first documented PD by BICR or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. As pre-specified by the protocol, PFS for Part 2 Cohort A was planned to be assessed by BICR and was to only include all participants randomized to Part 2 Cohort A who received at least one dose of study intervention.

Time frame:
Up to approximately 13 months

No measurements were reported for this outcome.

SecondaryPFS Per RECIST 1.1 as Assessed by Investigator - Part 1 & Part 2 Cohort B

PFS was defined as the time from randomization to the first documented PD by investigator or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS as assessed by the investigator is reported.

Time frame:
Up to approximately 13 months
Reported as:
Median · Months
PFS Per RECIST 1.1 as Assessed by Investigator - Part 1 & Part 2 Cohort B
MonthsPart 1: MK-1200 3.6 mg/kgPart 1: MK-1200 4.2 mg/kgPart 1: MK-1200 4.8 mg/kgPart 2: MK-1200 Cohort A (Part 2-Not Enrolled)Part 2: MK-1200 Cohort B (Part 2-Not Enrolled)
PFS Per RECIST 1.1 as Assessed by Investigator - Part 1 & Part 2 Cohort B2.9 (2.6 to NA)3.9 (1.5 to NA)1.3 (0.4 to NA)——
SecondaryOverall Survival (OS) - Part 1 & Part 2

OS was defined as the time from randomization to death due to any cause.

Time frame:
Up to approximately 13 months
Reported as:
Median · Months
Overall Survival (OS) - Part 1 & Part 2
MonthsPart 1: MK-1200 3.6 mg/kgPart 1: MK-1200 4.2 mg/kgPart 1: MK-1200 4.8 mg/kgPart 2: MK-1200 Cohort A (Part 2-Not Enrolled)Part 2: MK-1200 Cohort B (Part 2-Not Enrolled)
Overall Survival (OS) - Part 1 & Part 28.4 (4.1 to NA)4.6 (3.4 to NA)3.7 (1.6 to NA)——

Adverse events

Collected over Up to approximately 13 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: MK-1200 3.6 mg/kg2/3 (66.7%)1/3 (33.3%)3/3 (100%)
Part 1: MK-1200 4.2 mg/kg5/5 (100%)4/5 (80%)5/5 (100%)
Part 1: MK-1200 4.8 mg/kg4/5 (80%)0/5 (0%)5/5 (100%)
Most frequent serious events
Most frequent serious events
EventPart 1: MK-1200 3.6 mg/kgPart 1: MK-1200 4.2 mg/kgPart 1: MK-1200 4.8 mg/kg
Small intestinal obstructionGastrointestinal disorders0/32/50/5
Biliary obstructionHepatobiliary disorders1/30/50/5
Device occlusionProduct Issues1/30/50/5
AscitesGastrointestinal disorders0/31/50/5
SepsisInfections and infestations0/31/50/5
EmbolismVascular disorders0/31/50/5
Most frequent other events
Showing 10 of 58
Most frequent other events
EventPart 1: MK-1200 3.6 mg/kgPart 1: MK-1200 4.2 mg/kgPart 1: MK-1200 4.8 mg/kg
NauseaGastrointestinal disorders3/32/52/5
AnaemiaBlood and lymphatic system disorders1/34/50/5
FatigueGeneral disorders1/33/54/5
Abdominal painGastrointestinal disorders2/31/50/5
DizzinessNervous system disorders2/30/50/5
Decreased appetiteMetabolism and nutrition disorders1/33/51/5
NeutropeniaBlood and lymphatic system disorders0/32/51/5
AscitesGastrointestinal disorders0/32/50/5
VomitingGastrointestinal disorders0/32/52/5
AstheniaGeneral disorders0/32/50/5

Baseline characteristics

Baseline characteristics include data from 13 participants allocated to Part 1. No participants were enrolled in Part 2; therefore, no baseline characteristics data are reported for Part 2.

Age, Continuous
Age, Continuous(Years)Part 1: MK-1200 3.6 mg/kgPart 1: MK-1200 4.2 mg/kgPart 1: MK-1200 4.8 mg/kgPart 2: MK-1200 Cohort A (Part 2-Not Enrolled)Part 2: MK-1200 Cohort B (Part 2-Not Enrolled)Total
Mean63.7 ± 13.664.0 ± 8.762.0 ± 8.3——63.2 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: MK-1200 3.6 mg/kgPart 1: MK-1200 4.2 mg/kgPart 1: MK-1200 4.8 mg/kgPart 2: MK-1200 Cohort A (Part 2-Not Enrolled)Part 2: MK-1200 Cohort B (Part 2-Not Enrolled)Total
Female150006
Male205007
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: MK-1200 3.6 mg/kgPart 1: MK-1200 4.2 mg/kgPart 1: MK-1200 4.8 mg/kgPart 2: MK-1200 Cohort A (Part 2-Not Enrolled)Part 2: MK-1200 Cohort B (Part 2-Not Enrolled)Total
Hispanic or Latino011002
Not Hispanic or Latino3440011
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: MK-1200 3.6 mg/kgPart 1: MK-1200 4.2 mg/kgPart 1: MK-1200 4.8 mg/kgPart 2: MK-1200 Cohort A (Part 2-Not Enrolled)Part 2: MK-1200 Cohort B (Part 2-Not Enrolled)Total
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White3550013
More than one race000000
Unknown or Not Reported000000
08

Study locations

16 sites
  • The University of Louisville, James Graham Brown Cancer Center ( Site 0004)
    Louisville, Kentucky 40202, United States
  • START Midwest ( Site 0014)
    Grand Rapids, Michigan 49546, United States
  • South Texas Accelerated Research Therapeutics (START) ( Site 0005)
    San Antonio, Texas 78229, United States
  • START Mountain Region ( Site 0015)
    West Valley City, Utah 84119, United States
  • University of Virginia Health System-Hematology-Oncology ( Site 0009)
    Charlottesville, Virginia 22908, United States
  • The Alfred Hospital ( Site 0103)
    Melbourne, Victoria 3004, Australia
  • Bradfordhill-Clinical Area ( Site 0301)
    Santiago, Region M. de Santiago 8420383, Chile
  • Beijing Cancer hospital-Digestive Oncology ( Site 0401)
    Beijing, Beijing Municipality 100142, China
  • Fujian Cancer Hospital-oncology department ( Site 0409)
    Fuzhou, Fujian 350000, China
  • First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 0415)
    Huai'an, Jiangsu 223300, China
  • Rambam Health Care Campus-Oncology Division ( Site 0602)
    Haifa, 3109601, Israel
  • Hadassah Medical Center ( Site 0604)
    Jerusalem, 9112001, Israel
  • Rabin Medical Center-Oncology ( Site 0603)
    Petah Tikva, 4941492, Israel
  • Sheba Medical Center ( Site 0605)
    Ramat Gan, 5265601, Israel
  • Sourasky Medical Center ( Site 0601)
    Tel Aviv, 6423906, Israel
  • Samsung Medical Center-Division of Hematology/Oncology ( Site 1003)
    Seoul, 06351, South Korea
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Jun 2025, 15 months.

Results were first posted in Jun 2026, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2024
First posted
Feb 5, 2024
StartActual
Feb 28, 2024
Primary completionActual
Jun 17, 2025
CompletionActual
Jun 17, 2025
Results first posted
Jun 5, 2026
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06242691
Responsible party
Sponsor
First posted
Feb 5, 2024
Start date
Feb 28, 2024
Primary completion
Jun 17, 2025
Completion
Jun 17, 2025
Results posted
Jun 5, 2026
Last update
Jun 5, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200

Start the discussion